Artificial intelligence research biotech Earendil Labs has penned an $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates. | AI research biotech ...

Research-backed strategy produces highly homogeneous antibody-drug conjugates (gsADCs) with consistent DAR and tumor suppression lasting over 50 days after a single dose A new white paper from ...

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and ...

Antibody drug conjugates have fast become a big piece of AstraZeneca’s revenue growth. The drugmaker is taking steps to ensure it has the production capacity to meet market demand for these cancer ...

Less than a month after unveiling a peptide expansion at its production site in Mourenx, CDMO Axplora has hit the gas on a capacity-building project at another French plant. Axplora is bulking up at ...

Axplora invests $30 million in lyophilization at Le Mans site, boosting ADC production. Facilities enhance control, reliability, and traceability.

The "ADC Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody ...

First scalable single-use mixer specifically designed for ADC manufacturing Increases efficiency by 70% compared to stainless steel or glass manufacturing methods Utilizes Ultimus ® Film for superior ...

Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs) Reinforces position as first commercially approved contract development and manufacturing ...

With the precision of monoclonal antibodies and the potency of small-molecular payloads, antibody-drug conjugates (ADC) are promising cancer therapeutics. As of this year, there are 19 ADC drugs ...

-- Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. -- Chime Biologics will ...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany (Merck KGaA), invested $76 million to expand its antibody drug conjugate (ADC) manufacturing capabilities ...